Viewing Study NCT03874325



Ignite Creation Date: 2024-05-06 @ 12:53 PM
Last Modification Date: 2024-10-26 @ 1:05 PM
Study NCT ID: NCT03874325
Status: TERMINATED
Last Update Posted: 2022-05-31
First Post: 2019-03-12

Brief Title: Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer
Sponsor: H Lee Moffitt Cancer Center and Research Institute
Organization: H Lee Moffitt Cancer Center and Research Institute

Study Overview

Official Title: A Phase II Trial With Safety Run-in of Neoadjuvant Therapy With an Aromatase Inhibitor in Combination With Durvalumab MEDI4736 in Postmenopausal Patients With Hormone-Receptor-Positive Breast Cancer
Status: TERMINATED
Status Verified Date: 2022-05
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: lost funding
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This study is to find out if an investigational drug called Durvalumab MEDI4736 given together with a standard of care aromatase inhibitor drug can help people with breast cancer
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: True
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
ESR-17-13182 OTHER AstraZeneca None